3D-printed organ developer BioLife4D seeks $50 million IPO


BioLife4D 3D-printed organBiological 3D printing developer BioLife4D has filed for a $50 million initial public offering as it looks to commercialize its cardiac tissue regeneration and organ replacement processes.

The Chicago-based company said yesterday it is developing technologies with an end goal of creating a 3D bioprinted viable human heart suitable for transplant.

Funds from the offering are slated to support working capital and fund initiatives which include expanding personnel, acquiring additional laboratory space and licensing related technologies.

Read the full story on our sister site MassDevice.

Want to stay on top of MDO content? Subscribe to our e-newsletter.

Speak Your Mind